抗体治疗市场增长报告|规模和份额 2031

Publication Month : Jan 2024

  • Report Code : TIPRE00031447
  • Category : Biotechnology
  • Status : Upcoming
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

[研究报告]抗体治疗市场规模预计将从2022年的72.232亿美元增长到2023年的138.790亿美元;预计预测期内复合年增长率为 7.8%。

市场洞察和分析师观点:


< br>抗体疗法涉及使用单克隆抗体来靶向体内特定的致病分子。这些单克隆抗体可以大量生产并且具有高度特异性,这使得它们成为治疗多种疾病的有吸引力的选择。抗体疗法由模仿或改善人体自然免疫系统的人造蛋白质组成,其作用类似于人类抗体。抗体治疗市场是由癌症、自身免疫性疾病等慢性疾病的患病率不断上升以及传染病的增加推动的。此外,产品发布的增加以及靶向和个性化疗法的开发预计将进一步促进抗体疗法市场的增长。

增长动力和挑战:



传染病在世界范围内迅速增加。世界卫生组织 (WHO) 报告称,传染病每年可能导致超过 3000 万人死亡。根据 TB Facts Org 的最新报告,2021 年全球约有 1060 万人被诊断出患有结核病 (TB),较 2020 年的 1010 万人增加了 4.5%。此外,国际旅行的便捷性导致应对传染病变得更加复杂,从而导致了大流行。此外,全球气候条件的变化也加剧了传染病的流行,因为它会增加传染病的严重程度。根据联合国减少灾害风险办公室 (UNDR) 的数据,气候变化可使全球人类遭遇的传染病加剧 58%。

自 20 世纪 70 年代以来,已发现约 40 种传染病,包括 SARS、MERS、埃博拉病毒病、基孔肯雅热、禽流感、猪流感、寨卡病毒感染,以及最近, 2019冠状病毒病。根据美国疾病控制和预防中心 (CDC) 的数据,2020 年 9 月至 2021 年 5 月期间,美国临床实验室检测的 818,939 份呼吸道样本中,有 1,675 份呈流感病毒阳性。此外,人口老龄化的加剧以及社会行为和生活方式的变化导致了一些常见的长期健康状况。根据世界卫生组织 (WHO) 的预测,到 2026 年底,慢性生活方式疾病的患病率预计将增加 57%。新兴市场将受到最严重的打击,因为发展中国家的人口预计将出现爆炸式增长。随着城市化进程的不断加快,人们更倾向于久坐的生活方式,从而导致类风湿性关节炎、糖尿病等疾病的发生。糖尿病是21世纪全球主要健康问题之一。根据国际糖尿病联盟(IDF)的数据,2019年北美糖尿病患者人数约为4600万,预计到2045年将达到6200万。预测期内疾病患病率增加约35% 。因此,全球范围内传染性和慢性疾病的增加预计将推动抗体治疗市场的增长。

然而,抗体治疗的可用性仅限于有限的特定区域或国家(主要包括发达地区)使得难以接触到来自发展中经济体的一些患者。此外,与其开发相关的高成本增加了抗体疗法的价格以及相关的副作用,预计这将阻碍抗体疗法市场的增长。

战略见解

报告细分和范围:



“全球抗体治疗市场”规模”根据类型、最终用户和地理位置进行细分。根据类型,抗体治疗市场分为单克隆抗体和抗体药物偶联物。单克隆抗体细分市场进一步分为肿瘤学、自身免疫性疾病、传染病等。根据最终用户,抗体治疗市场分为医院、专科中心等。根据地理位置,抗体治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、俄罗斯和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国、亚太地区其他地区)、中东和美国非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美和非洲中美洲(巴西、阿根廷以及南美洲和中美洲其他地区)。

细分分析:



根据类型,抗体治疗市场规模分为单克隆抗体和抗体药物偶联物。此外,单克隆抗体分为肿瘤学、自身免疫性疾病、传染病等。 2022年,单克隆抗体领域占据最大市场份额。由于应用领域不断增加,包括癌症、自身免疫性疾病、传染病等,预计未来几年将以更高的复合年增长率增长。单克隆抗体旨在针对体内的特定蛋白质或细胞,因为它们是精确的,并且可以针对特定疾病进行定制。单克隆抗体已用于治疗一系列疾病,包括癌症、自身免疫性疾病和传染病。

此外,癌症、传染病、自身免疫性疾病和传染病的患病率不断增加其他预计将为整体市场增长做出贡献。例如,根据世界卫生组织的数据,2020 年全球报告了约 1,900 万新的癌症病例。此外,根据美国疾病控制与预防中心 (CDC) 的数据,约 1,020 万人前往医生办公室治疗传染病和寄生虫病每年在非洲国家。基于单克隆抗体的疗法具有多种优点,包括特异性高、副作用少、制造工艺简单、可以大批量生产。市场上有各种基于单克隆抗体的疗法,包括用于乳腺癌的赫赛汀、用于非霍奇金淋巴瘤的利妥昔单抗以及用于不同类型癌症的Keytruda。除此之外,各种基于单克隆的抗体正在开发中,预计将在不久的将来推出,为抗体治疗市场的增长做出贡献。

抗体治疗市场,按类型 - 2022 年和 2030 年

基于对于最终用户,抗体治疗市场分为医院、专科诊所等。 2022 年,医院细分市场占据最大市场份额,预计在预测期内复合年增长率最高。医院是最受欢迎的治疗医疗机构之一。抗体疗法通常通过静脉输注或注射进行,患者在数周或数月内接受常规剂量。医院通常设有专门的输液中心或诊所,致力于为患者群体提供抗体治疗。此外,医院、其他医疗机构和医疗基础设施数量的不断增加,以及全球大量人口对医院的便捷访问和可用性,预计将推动医院领域的增长。此外,不同专家和服务的集中提供,以及先进的治疗和治疗后护理,预计也将促进抗体治疗市场的增长。

< span>区域分析:



根据地理位置,抗体治疗市场分为五个关键区域:北美、欧洲、亚太地区、南美和中东地区。中美洲、中东和非洲非洲。 2022年,北美占据最大的抗体治疗市场份额,紧随其后的是欧洲,预计亚太地区在预测期内的复合年增长率最高。北美市场的增长主要是由慢性病和传染病患病率的增加以及该地区重要市场参与者的存在推动的。根据国家多发性硬化症协会的数据,到 2022 年,美国约有 100 万人患有多发性硬化症。该地区的制造商参与了抗体疗法的研发活动,可用于治疗各种病症,包括癌症、自身免疫性疾病等。研究活动的增加带来了创新、新产品发布、产品批准等,预计将推动抗体治疗市场的增长。美国是北美地区的发达国家之一,占据主要市场,预计在预测期内将适度发展。

此外,战略合作有所增加各个市场参与者对抗体疗法的开发预计将支持抗体疗法市场的增长。例如,2020 年 3 月,AbCellera 和礼来公司将从 500 多种独特抗体中进行选择,这些抗体是从美国第一批从 COVID-19 中康复的患者中分离出来的,以创建用于治疗和预防 COVID-19 的抗体疗法。此次合作将利用 AbCellera 在 DARPA 流行病预防平台 (P3) 计划下开发的快速流行病应对平台,以及礼来公司快速开发、制造和分销治疗性抗体的全球能力。

然而,亚太地区成为全球抗体治疗市场增长最快的地区。该地区的市场预计将在中国、日本和印度等国家显着增长。该市场的增长归因于市场参与者对发展中经济体的日益关注以及慢性病和传染病的患病率不断上升,以及基于抗体的生物制剂的使用不断增加。此外,该地区研发活动的增加促进了新产品的开发,以支持该地区的产品发布。例如,2022年7月,Brii Biosciences Limited和TSB Therapeutics(北京)有限公司在中国推出了amubavimab/romlusevimab组合,一种长效的COVID-19中和抗体疗法。 7月7日,第一批商业化抗体上市,标志着联合疗法商业化的重要里程碑。此外,印度、中国和日本等国家医疗保健支出的增加和对靶向治疗的需求不断增长预计将促进市场增长。

日本拥有完善的医疗保健体系,癌症患病率较高,使其成为抗体治疗的重点国家。此外,印度和中国人口众多,预计将增加对包括抗体疗法在内的先进医疗保健治疗的需求。此外,该地区还有一些主要市场参与者,包括百时美施贵宝、默沙东和默沙东。公司、诺华公司和其他公司大力投资研发,重点关注新抗体疗法的开发及其在该地区的扩张,因为该地区提供了充足的增长机会。因此,上述所有因素预计将在不久的将来推动抗体治疗市场的增长。

行业发展和未来机遇:< /strong>

全球抗体治疗市场主要参与者采取的各种举措如下:

1 。 2023 年 9 月,德克萨斯大学 MD 安德森癌症中心和 Panacea Venture 宣布成立 Manaolana Oncology Inc.,这是一家新公司,旨在开发和推进针对新型癌症抗原的基于抗体的疗法。

2。 2022 年 3 月,赛诺菲和 Seagen Inc.合作设计、开发和商业化针对多达三个癌症靶标的抗体药物偶联物 (ADC)。此次合作将利用赛诺菲专有的单克隆抗体 (mAb) 技术和 Seagen 的专有 ADC 技术。 ADC 是一种抗体,旨在向表达特定蛋白质的肿瘤细胞输送有效的抗癌药物,赛诺菲目前正在开发一种 ADC。

3. 2022 年 1 月,Fate Therapeutics, Inc. 收到了美国食品和药物管理局 (FDA) 的 FT536 试验性新药 (IND) 申请,FT536 是一种现成的、多重工程的、iPSC 衍生的嵌合药物。抗原受体(CAR)NK细胞候选产品。公司计划启动 FT536 作为单一疗法以及与肿瘤靶向单克隆抗体疗法联合治疗多种实体瘤适应症的临床研究。

4. 2020 年 7 月,阿斯利康与第一三共株式会社 (Daiichi Sankyo) 就 DS-1062 达成新的全球开发和商业化协议,DS-1062 是第一三共专有的滋养层细胞表面抗原 2 (TROP2) 导向的抗体药物偶联物 ( ADC)和治疗多种肿瘤类型的潜在新药。

竞争格局和主要公司:

全球抗体治疗市场的一些知名参与者包括默克公司(Merck & Inc.)。 Co. Inc、礼来公司、Seagen、诺华公司、武田制药、百时美施贵宝、强生公司约翰逊、阿斯利康、再生元制药公司、安进等。这些公司专注于新产品发布和地域扩张,以满足全球不断增长的消费者需求,并增加其专业产品组合的产品范围。他们在全球范围内拥有广泛的业务,这使他们能够为大量客户提供服务,从而提高他们的市场份额。

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

  • Merck & Co. Inc
  • Eli Lilly and Company
  • Seagen
  • Novartis AG
  • Takeda Pharmaceuticals
  • Bristol-Myers Squibb
  • Johnson & Jhonson
  • AstraZeneca
  • Regeneron Pharmaceuticals Inc
  • Amgen

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports